Wednesday, 16 September, 2026
From Algorithms to Prescriptions: ByteDance’s AI Drug Discovery Spinoff Secures $290M
By TechShots Studio
ByteDance has completed a $290 million external fundraising round for its newly spun-off AI drug discovery unit, Anew Labs, reaching a $1.5 billion valuation. Led by prominent venture firms including HSG, IDG Capital, and Hillhouse, the independent spin-off allows the biotech startup to operate under specialized industry management while ByteDance retains a controlling 56% majority stake.